MacroGenics Inc. Stock

Price

Target price

/ Stuttgart Stock Exchange WKN: A1W6ND / Symbol: MGNX / Name: MacroGenics / Stock / Biotechnology & Medical Research / Small Cap /

Please give a prediction to see the opinions of the community

Buy

None

Sell

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

JS chart by amCharts

From: to:

Zoom:

Your prediction

MacroGenics Inc. Stock

A loss of -1.160% shows a downward development for MacroGenics Inc..

Our community is currently high on MacroGenics Inc. with 5 Buy predictions and 1 Sell predictions.

Based on the current price of 1.2 € the target price of 8 € shows a potential of 567.78% for MacroGenics Inc. which would more than double the current price.

For the coming years our community has positive and negative things to say abot the MacroGenics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Valuation (undervalued/overvalued)" there were negative voices in the community.

What does MacroGenics do?

Pros and Cons of MacroGenics Inc. in the next few years

Pros

B****

W********* I********* f** t** n*** y****

C******** o* t** e**********

Cons

M***** P*******

S********** s********

G***** c******* t* c**********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of MacroGenics Inc. vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
MacroGenics Inc.
Krystal Biotech
Ardelyx Inc.
Evolus Inc

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2024-08-01

MacroGenics, Inc. (NASDAQ: MGNX) operates in the Biotechnology & Medical Research industry, focusing on innovative therapies for cancer treatment. The financials reveal a company grappling with significant operational challenges but also charting a path through strategic investments and potential revenue growth. While the overall impression indicates distress in earnings and profitability, there are areas worth exploring, including cash management, investments in R&D, and future revenue potential that could influence the company’s recovery and growth.

Liquidity Position: MacroGenics ended 2023 with a cash balance of $100.96 million. This indicates a relatively healthy liquidity position that can help sustain operations in the near term, especially crucial for a biotech firm where cash flows can be irregular and dependent on clinical milestones and regulatory approval timelines.

Strategic Investments: The company reported capital expenditures of approximately $1.76 million while managing cash flows from financing activities of $150.36 million. This indicates an ability to raise funds, possibly for further development or marketing of their products, positioning MacroGenics to capitalize on future opportunities.

Feedback

Comments

Prediction Buy

Perf. (%)

Target price 2.681

Change

Ends at

MacroGenics, Inc. (NASDAQ: MGNX) had its "overweight" rating re-affirmed by analysts at Barclays PLC. They now have a $3.00 price target on the stock, down previously from $8.00.

Ratings data for MGNX provided by MarketBeat